Check-Cap Ltd., a clinical stage medical diagnostics company, focuses on capsule-based screening technology products. The company is headquartered in Isfiya, Israel.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-2.21M |
| Operating Margin | 0.00% |
| Return on Equity | 41.70% |
| Return on Assets | -37.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.49 |
| Price-to-Book | 2.41 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 1.85 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $7.73M |
| Float | $5.61M |
| % Insiders | 37.48% |
| % Institutions | 0.46% |
Volatility is currently expanding
ISFIYA, Israel and LAS VEGAS, July 16, 2026 (GLOBE NEWSWIRE) -- Check-Cap Ltd. (“Check-Cap” or the “Company”) (NASDAQ: MBAI) today announced that its merger partner, MBody AI Corp. (“MBody AI”), has added multi-robot fleet control to the MBody AI Orchestrator (the “Orchestrator”), its proprietary AI-driven enterprise software platform.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MBAI and any ticker you trade — then tracks every position and per-strategy win rate.
